Senetek plc is a life sciences company, engaged in the development of technologies for the science of healthy aging. It operates in two segments, Skincare and Pharmaceutical. The Skincare segment markets and sells Pyratine-6, a second generation cytokinin for the treatment of aging skin; and Pyratine XR for the visible signs and symptoms associated with various conditions, such as rosacea, eczema, contact dermatitis, and menopause.
It is also developing 4HBAP, an aromatic cytokinin that has completed clinical tests for the treatment of photodamaged skin. The Pharmaceutical segment provides Invicorp, an intracavernous injection therapy for the treatment of male erectile dysfunction; Reliaject, an auto-injector system, which employs an ultra-fine gauge needle, preset to achieve the appropriate penetration before drug flow occurs; and diagnostic monoclonal antibodies used in Alzheimer’s and other disease research. The company has a research and collaboration agreement with the Institute of Experimental Botany for various applications to any cytokinin developed, in-licensed, or acquired by the Institute; and the right to co-exploit with the Institute any cytokinins that Senetek does not elect to in-license.
As of March 17, 2011, Senetek plc was acquired by Independence Resources Plc, in a Reverse merger transaction.